| pubmed-article:2457657 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2457657 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:2457657 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:2457657 | lifeskim:mentions | umls-concept:C0010934 | lld:lifeskim |
| pubmed-article:2457657 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:2457657 | lifeskim:mentions | umls-concept:C0205851 | lld:lifeskim |
| pubmed-article:2457657 | lifeskim:mentions | umls-concept:C0005740 | lld:lifeskim |
| pubmed-article:2457657 | lifeskim:mentions | umls-concept:C0008838 | lld:lifeskim |
| pubmed-article:2457657 | lifeskim:mentions | umls-concept:C0010583 | lld:lifeskim |
| pubmed-article:2457657 | lifeskim:mentions | umls-concept:C0015133 | lld:lifeskim |
| pubmed-article:2457657 | lifeskim:mentions | umls-concept:C0042670 | lld:lifeskim |
| pubmed-article:2457657 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:2457657 | pubmed:dateCreated | 1988-9-26 | lld:pubmed |
| pubmed-article:2457657 | pubmed:abstractText | Standard chemotherapy for disseminated germ cell tumors (GCT) cures most patients but causes considerable acute toxicity, including treatment-related death due to septicemia during neutropenia and pulmonary fibrosis. In addition, chronic and delayed toxicities, particularly Raynaud's phenomenon, have been reported in 6% to 37% of treated patients. In an attempt to minimize the acute and chronic effects of treatment which are related primarily to vinblastine and bleomycin, a randomized trial comparing the efficacy and toxicity of vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin (VAB-6) and etoposide + cisplatin (EP) was conducted on 164 eligible patients with good-prognosis GCT. Seventy-nine of 82 (96%) patients receiving VAB-6 and 76/82 (93%) receiving EP achieved a complete remission (CR) with or without adjunctive surgery. Similar proportions of patients in both arms were found at surgery to have necrosis/fibrosis or mature teratoma. With a median follow-up of 24.4 months in the VAB-6 arm and 25.9 months in the EP arm, the total, relapse-free, and event-free survival distributions were similar in the two arms. Patients receiving EP experienced less emesis (P = .05), higher nadir WBC (P = .06) and platelet counts (P = .01), less magnesium wasting (P = .0001), less mucositis (P = .09), and no pulmonary toxicity. No treatment-related mortality was observed. EP is an efficacious and less toxic regimen and is recommended for good-prognosis patients with disseminated GCT. | lld:pubmed |
| pubmed-article:2457657 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2457657 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2457657 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2457657 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2457657 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2457657 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2457657 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2457657 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2457657 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2457657 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2457657 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2457657 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2457657 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:2457657 | pubmed:issn | 0732-183X | lld:pubmed |
| pubmed-article:2457657 | pubmed:author | pubmed-author:GolbeyR BRB | lld:pubmed |
| pubmed-article:2457657 | pubmed:author | pubmed-author:YagodaAA | lld:pubmed |
| pubmed-article:2457657 | pubmed:author | pubmed-author:BoslG JGJ | lld:pubmed |
| pubmed-article:2457657 | pubmed:author | pubmed-author:VogelzangN... | lld:pubmed |
| pubmed-article:2457657 | pubmed:author | pubmed-author:CareyRR | lld:pubmed |
| pubmed-article:2457657 | pubmed:author | pubmed-author:GellerN LNL | lld:pubmed |
| pubmed-article:2457657 | pubmed:author | pubmed-author:ScherHH | lld:pubmed |
| pubmed-article:2457657 | pubmed:author | pubmed-author:BajorinDD | lld:pubmed |
| pubmed-article:2457657 | pubmed:author | pubmed-author:AumanJJ | lld:pubmed |
| pubmed-article:2457657 | pubmed:author | pubmed-author:LeitnerS PSP | lld:pubmed |
| pubmed-article:2457657 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2457657 | pubmed:volume | 6 | lld:pubmed |
| pubmed-article:2457657 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2457657 | pubmed:authorsComplete | N | lld:pubmed |
| pubmed-article:2457657 | pubmed:pagination | 1231-8 | lld:pubmed |
| pubmed-article:2457657 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:2457657 | pubmed:meshHeading | pubmed-meshheading:2457657-... | lld:pubmed |
| pubmed-article:2457657 | pubmed:meshHeading | pubmed-meshheading:2457657-... | lld:pubmed |
| pubmed-article:2457657 | pubmed:meshHeading | pubmed-meshheading:2457657-... | lld:pubmed |
| pubmed-article:2457657 | pubmed:meshHeading | pubmed-meshheading:2457657-... | lld:pubmed |
| pubmed-article:2457657 | pubmed:meshHeading | pubmed-meshheading:2457657-... | lld:pubmed |
| pubmed-article:2457657 | pubmed:meshHeading | pubmed-meshheading:2457657-... | lld:pubmed |
| pubmed-article:2457657 | pubmed:meshHeading | pubmed-meshheading:2457657-... | lld:pubmed |
| pubmed-article:2457657 | pubmed:meshHeading | pubmed-meshheading:2457657-... | lld:pubmed |
| pubmed-article:2457657 | pubmed:meshHeading | pubmed-meshheading:2457657-... | lld:pubmed |
| pubmed-article:2457657 | pubmed:meshHeading | pubmed-meshheading:2457657-... | lld:pubmed |
| pubmed-article:2457657 | pubmed:meshHeading | pubmed-meshheading:2457657-... | lld:pubmed |
| pubmed-article:2457657 | pubmed:meshHeading | pubmed-meshheading:2457657-... | lld:pubmed |
| pubmed-article:2457657 | pubmed:meshHeading | pubmed-meshheading:2457657-... | lld:pubmed |
| pubmed-article:2457657 | pubmed:meshHeading | pubmed-meshheading:2457657-... | lld:pubmed |
| pubmed-article:2457657 | pubmed:meshHeading | pubmed-meshheading:2457657-... | lld:pubmed |
| pubmed-article:2457657 | pubmed:meshHeading | pubmed-meshheading:2457657-... | lld:pubmed |
| pubmed-article:2457657 | pubmed:meshHeading | pubmed-meshheading:2457657-... | lld:pubmed |
| pubmed-article:2457657 | pubmed:meshHeading | pubmed-meshheading:2457657-... | lld:pubmed |
| pubmed-article:2457657 | pubmed:meshHeading | pubmed-meshheading:2457657-... | lld:pubmed |
| pubmed-article:2457657 | pubmed:year | 1988 | lld:pubmed |
| pubmed-article:2457657 | pubmed:articleTitle | A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. | lld:pubmed |
| pubmed-article:2457657 | pubmed:affiliation | Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021. | lld:pubmed |
| pubmed-article:2457657 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2457657 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:2457657 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:2457657 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:2457657 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:2457657 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2457657 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2457657 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2457657 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2457657 | lld:pubmed |
